Want to see NRC full AI Analyst Report?
NRC Stock Chart & Stats
$21.04
$0.41(1.95%)
At close: 4:00 PM EDT
$21.04
$0.41(1.95%)
Day’s Range― - ―
52-Week Range$11.01 - $23.68
Previous CloseN/A
Volume19.56K
Average Volume (3M)102.91K
Market Cap
$439.69M
Enterprise Value$561.44
Total Cash (Recent Filing)$3.33M
Total Debt (Recent Filing)$90.03M
Price to Earnings (P/E)74.3
Beta0.69
Next Earnings
Nov 03, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend Yield3.08%
Share Statistics
EPS (TTM)0.26
Shares Outstanding22,536,695
10 Day Avg. Volume100,181
30 Day Avg. Volume102,911
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)30.03
Price to Sales (P/S)3.06
P/FCF Ratio26.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$26.00Price Target Upside23.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.34
Revenue Forecast (FY)$142.00M
Bulls Say, Bears Say
Bulls Say
Cash GenerationImproving and positive TTM operating cash flow and a meaningful increase in free cash flow provide durable financial flexibility. Over the next 2–6 months this enhances the company's ability to service debt, fund product commercialization and go-to-market investments, and absorb short-term revenue variability without immediate capital raises.
Recurring Revenue ModelA subscription/recurring fee business tied to patient experience and employee engagement creates high revenue visibility and client stickiness. This structural model supports predictable cash flows, cross-sell of analytics and advisory services, and long-term client relationships that sustain revenue and margin recovery opportunities.
Governance ReformsRecent shareholder-approved governance reforms increase board accountability and shareholder influence, reducing entrenchment risks. Structurally, clearer governance can improve capital-allocation discipline, facilitate strategic decision-making, and attract longer-term investors supportive of operational fixes and growth initiatives.
Bears Say
High LeverageExceptionally high leverage driven by a very small equity base materially reduces financial flexibility and raises refinancing and covenant risks. Over months, elevated interest burdens and constrained capacity for M&A or large investments can limit strategic responses to competition or slow margin recovery, increasing downside risk in stress scenarios.
Margin CompressionSustained drop in gross and net margins signals structural pressure on profitability, reducing internal capital for R&D, sales expansion, and debt paydown. If margins remain compressed, the company may struggle to rebuild earnings power even with stable revenue, weakening long-term returns and resilience to cost or pricing shocks.
Weak Revenue TrendA multi-year weaker revenue trend limits economies of scale and hampers margin recovery. Without a sustained improvement in organic growth or durable expansion of product adoption, the company faces pressure on reinvestment, pricing power, and the ability to expand EBITDA, constraining durable upside over the medium term.
National Research News
NRC FAQ
What was National Research Corp’s price range in the past 12 months?
National Research Corp lowest stock price was $11.01 and its highest was $23.68 in the past 12 months.
What is National Research Corp’s market cap?
National Research Corp’s market cap is $439.69M.
When is National Research Corp’s upcoming earnings report date?
National Research Corp’s upcoming earnings report date is Nov 03, 2026 which is in 93 days.
How were National Research Corp’s earnings last quarter?
National Research Corp released its earnings results on Jul 28, 2026. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.46.
Is National Research Corp overvalued?
According to Wall Street analysts National Research Corp’s price is currently Undervalued.
Does National Research Corp pay dividends?
National Research Corp pays a Quarterly dividend of $0.16 which represents an annual dividend yield of 3.08%. See more information on National Research Corp dividends here
What is National Research Corp’s EPS estimate?
National Research Corp’s EPS estimate is 0.21.
How many shares outstanding does National Research Corp have?
National Research Corp has 22,536,695 shares outstanding.
What happened to National Research Corp’s price movement after its last earnings report?
National Research Corp reported an EPS of $0.31 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went down -18.084%.
Which hedge fund is a major shareholder of National Research Corp?
Currently, no hedge funds are holding shares in NRC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
National Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.00 (23.57% Upside)
$26.00 (23.57% Upside)
Blogger Sentiment
Neutral
NRC Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 60.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.79%
12-Months-Change
Fundamentals
Return on Equity
3.08%
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Company Description
National Research Corp
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
NRC Company Deck
NRC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful progress across leading indicators (TRCV +8%, new sales +86%, highest retention in 7+ years), strong profitability (29% adjusted EBITDA margin) and clear product/organizational momentum (Rounding TRCV nearly doubled, AI initiatives, strategic hires). The primary negatives were a 4% full-year revenue decline and lingering impacts from elevated TRCV attrition in H2 2024 that created tough comps and pressured 2025 revenue. Management framed the revenue weakness as largely cyclical and expectant of recovery in 2026 as TRCV converts to recognized revenue. Overall, positive operational and financial fundamentals outweigh the near-term revenue drag.View all NRC earnings summariesNRC Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$26.00
▲(23.57% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Phreesia
―
Health Catalyst
―
Doximity
―
Definitive Healthcare Corp
―
Waystar Holding Corp.
―
Ownership Overview
2.78% Insiders
16.11% Mutual Funds
2.69% Other Institutional Investors
69.40% Public Companies and
Individual Investors












